Merck & Co., Whitehouse Station, N.J., said it reached a definitive agreement to acquire Avecia Biologics, Billingham, England, for an undisclosed amount.
Merck reaches deal to acquire U.K. biologics company
The deal will expand the Merck's biopharmaceutical manufacturing capacity, the company said in a news release. Avecia Biologics, owned by privately held Avecia Investments, specializes in microbial-derived biologics and has targeted cancer, heart disease and stroke medicines. The companies did not release an expected date to finalize the deal, which must first be approved by regulators and is subject to customary closing conditions, the news release said.
What do you think? Post a comment on this article and share your opinion with other readers. Submit your comments to Modern Healthcare Online at [email protected]. Please be sure to include your hometown and state, along with your organization and title.
Letter
to the
Editor
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.
Sponsored Content